Quantcast

Industry news that matters to you.  Learn more

Definiens to Host the First International Symposium for Tissue Phenomics This Fall

Reading time: 4 – 6 minutes

Definiens, the global leader in Tissue Phenomics™ for oncology diagnostics, recently announced that registration is now open for the company’s inaugural conference, The International Symposium for Tissue Phenomics. Alongside genomics, Tissue Phenomics is a key driver in the growth of personalized medicine, and the symposium brings together thought leaders from around the globe on companion diagnostics, immunotherapy, and tissue-based patient stratification for personalized medicine. The Symposium will begin with a keynote lecture from Nobel Laureate, Gerd Binnig, Ph.D., discussing his approach to uncovering novel diagnostics through using big data in tissue.

Key presentations and sessions at The International Symposium for Tissue Phenomics will include:

 
 

1.

 

Keynote Presentations:

       

 

“Tissue Phenomics – The Big Data Approach in Pathology,” by Gerd Binnig, Ph.D., Nobel Laureate, Founder, and Chief Technology Officer, Definiens

       

 

“Immunoscore / Immunoprofile: Assessing Anti-Cancer Immunity as a Biomarker to Stratify Patients for Clinical Trials,” by Carlo Bifulco, MD, Medical Director of Oncological Molecular Pathology and Pathology Informatics & Director of Translational Molecular Pathology, Providence Oregon Regional Laboratory & Earle A. Chiles Research Institute

 
 

2.

 

Session: Hypothesis or Big Data Driven Biomarker Discovery: Highlighting the latest work on the discovery of biomarkers and novel tissue signatures for patient stratification.

 
 

3.

 

Session: Immunotherapy and Tumor Microenvironment: Exploring the importance of the tumor microenvironment and the approaches being utilized for immuno-oncology scoring.

 
 

4.

 

Session: Assay Optimization, Standardization, and Validation: Focusing on assay development and practical approaches to optimize scalability and validation in preparation for PMA approval or IND filing.

 
 

5.

 

Session: Clinical Trials, Diagnostics, and Companion Diagnostic Tests: Discussing strategic issues in bringing tests to market, reimbursement, and commercialization.

 

“This is a very exciting year for the biopharma industry given the large strides made in immunotherapy and personalized medicine,” said Thomas Heydler, CEO of Definiens. “We are proud to host the first-ever industry event to engage in discussions and collaborations around Tissue Phenomics. Our goal is to establish the Symposium as a cornerstone in education and dialogue among key industry professionals for the continued advancement and innovation of Tissue Phenomics and cancer diagnostics.”

The symposium will take place from October 17-18, 2014, at the Hilton San Francisco Financial District in San Francisco. Register online at https://www.regonline.com/definiens_symposium_2014.

For more information, please contact Definiens at DefiniensSymposium@thecastlegrp.com or by phone at +1-617-337-9522.

Source: Business Wire